A phase I study of oral panobinostat (LBH589) alone and in combination with docetaxel (Doc) and prednisone in castration-resistant prostate cancer (CRPC)

被引：3
作者：
Rathkopf, D. E.
Wong, B. Y.
Ross, R. W.
George, D. J.
Picus, J.
Tanaka, E.
Chen, Y.
Atadja, P.
Yang, W.
Culver, K. W.
Scher, H. I.
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Nevada Canc Inst, Las Vegas, NV USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Duke Univ, Med Ctr, Durham, NC USA
[5] Washington Univ, St Louis, MO USA
[6] Novartis Inst Biomed Res, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.5152
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5152
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase Ib Study of Enzalutamide in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer
    Morris, Michael J.
    Rathkopf, Dana E.
    Novotny, William
    Gibbons, Jacqueline A.
    Peterson, Amy C.
    Khondker, Zakaria
    Ouatas, Taoufik
    Scher, Howard I.
    Fleming, Mark T.
    CLINICAL CANCER RESEARCH, 2016, 22 (15) : 3774 - 3781
  • [42] Docetaxel in combination with estramustine and prednisolone for castration-resistant prostate cancer
    Kuramoto, Tomomi
    Inagaki, Takeshi
    Fujii, Reona
    Sasaki, Yumiko
    Nishizawa, Satoshi
    Nanpo, Yoshihito
    Matusmura, Nagahide
    Kohjimoto, Yasuo
    Hara, Isao
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2013, 18 (05) : 890 - 897
  • [43] Phase I study of LBH589 in combination with erlotinib for advanced aerodigestive tract cancers
    Gray, J. E.
    Haura, E. B.
    Chiappori, A.
    Tanvetyanon, T.
    Williams, C. C.
    Pinder, M. C.
    Neuger, A.
    Giglia, J. L.
    Bepler, G.
    Altiok, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [44] Docetaxel in combination with estramustine and prednisolone for castration-resistant prostate cancer
    Tomomi Kuramoto
    Takeshi Inagaki
    Reona Fujii
    Yumiko Sasaki
    Satoshi Nishizawa
    Yoshihito Nanpo
    Nagahide Matusmura
    Yasuo Kohjimoto
    Isao Hara
    International Journal of Clinical Oncology, 2013, 18 : 890 - 897
  • [45] Cediranib (AZD2171) in docetaxel-resistant, castration-resistant prostate cancer (CRPC)
    Karakunnel, J. J.
    Gulley, J. L.
    Arlen, P.
    Mulquin, M.
    Wright, J.
    Turkbey, I. B.
    Choyke, P.
    Figg, W. D.
    Dahut, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [46] CASTRATION-RESISTANT PROSTATE CANCER (CRPC): A UK EPIDEMIOLOGY STUDY
    Morgan, C.
    McEwan, P.
    Chamberlain, G.
    Cabrera, C.
    Parry, D.
    VALUE IN HEALTH, 2010, 13 (03) : A26 - A26
  • [47] A phase I/II randomized study of panobinostat and bicalutamide in castration-resistant prostate cancer (CRPC) patients progressing on second-line hormone therapy
    Ferrari, A. C.
    Stein, M. N.
    Alumkal, J. J.
    Gomez-Pinillos, A.
    Catamero, D. D.
    Mayer, T. M.
    Collins, F.
    Beer, T. M.
    DiPaola, R. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [48] A Phase II Study of Oral Panobinostat (LBH589) in Adult Patients with Advanced Refractory Multiple Myeloma.
    Wolf, Jeffrey Lee
    Siegel, David
    Matous, Jeffrey
    Lonial, Sagar
    Goldschmidt, Hartmut
    Schmitt, Stefan
    Vij, Ravi
    De Malgalhaes-Silverman, Margarida
    Abonour, Rafat
    Jalaluddin, Muhammad
    Li, Martha
    Hazell, Katharine
    Bourquelot, Priscille M.
    Mateos, Maria-Victoria
    Anderson, Kenneth C.
    Spencer, Andrew
    Harousseau, Jean-Luc
    Blade, Joan
    BLOOD, 2008, 112 (11) : 957 - 957
  • [49] Dose-finding and efficacy phase II study of inecalcitol, a new VDR agonist, in combination with docetaxel-prednisone regimen for patients (pts) with castration-resistant prostate cancer (CRPC).
    Medioni, J.
    Ferrero, J.
    Deplanque, G.
    Maurina, T.
    Rodier, J. P.
    Raymond, E.
    Allyon, J.
    Renaux, S.
    Dufour-Lamartinie, J.
    Oudard, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [50] Dose-finding and efficacy phase II study of inecalcitol, a new VDR agonist, in combination with docetaxel-prednisone regimen for castration-resistant prostate cancer (CRPC) patients (pts)
    Medioni, J.
    Deplanque, G.
    Ferrero, J.
    Maurina, T.
    Rodier, J. P.
    Raymond, E.
    Allyon, J.
    Renaux, S.
    Dufour-Lamartinie, J.
    Oudard, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
12345